PAVmed Inc.'s majority owned subsidiary, Lucid Diagnostics, entered into subscription agreements for the sale of 5,000 shares of Series A-1 Preferred Stock, raising $5.0 million in a private placement.
AI Assistant
PAVMED INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.